AtriCure, Inc. reported 2026 quarter results with revenue of $153.6M, up 12.8% from $136.14M a year earlier, and diluted EPS of $0.18 compared with ($0.13) in the prior-year quarter as the company returned to net income of $8.96M versus a loss of ($6.19M).
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$153.6M$136.14M12.8% | Net income²$8.96M($6.19M)244.7% | Diluted EPS³$0.18($0.13)238.5% |
¹ Reported as “Revenue”. ² Reported as “Net income (loss)”. ³ Reported as “Diluted net income (loss) per share”.
Business Highlights
- Revenue growth of about 13% was driven by strong U.S. demand and improvements in product mix.
- Minimally invasive ablation procedures declined about 24% as physicians increasingly adopt pulsed field ablation (PFA) catheters, shifting procedure mix.
- Brand momentum continued for pain management, open ablation (EnCompass) and appendage devices (AtriClip FLEX/PRO-Mini).
- Regulatory and product progress included CE mark clearance for AtriClip FLEX-Mini and PRO-Mini; R&D and clinical programs such as LeAAPS and BoxX-NoAF remain active.
- Expanded training and adoption support — including virtual proctoring, CADet simulation and global streaming — to scale physician education.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.